Ascendis Pharma A/S or MorphoSys AG: Who Manages SG&A Costs Better?

Ascendis Pharma A/S vs. MorphoSys AG: A Decade of SG&A Management

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Ascendis Pharma A/S and MorphoSys AG have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Ascendis Pharma A/S saw a staggering increase in SG&A expenses, growing by over 4,100%, from approximately $6.3 million to $264 million. In contrast, MorphoSys AG's SG&A expenses peaked in 2021 at nearly $200 million but have since decreased by over 50% to around $92 million in 2023.

This trend highlights Ascendis Pharma's aggressive expansion strategy, while MorphoSys AG appears to be optimizing its operational efficiency. As investors and industry analysts evaluate these companies, understanding their SG&A management strategies provides valuable insights into their long-term financial health and strategic priorities.